Trial Profile
A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary) ; Lanreotide; Octreotide
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Acronyms PAOLA
- Sponsors Novartis Pharmaceuticals
- 01 Jun 2020 Results assessing the extent of comorbidities at baseline and outcomes during a long-term extension published in the European Journal of Endocrinology
- 28 Apr 2017 Status changed from active, no longer recruiting to completed.
- 25 Apr 2017 This trial has been completed in Poland (end date: 28 Feb 2017).